Proficiency Testing/EQA / 2020 Surveys / Genetics and Molecular Pathology / Biochemical and Molecular Genetics Help Please log in to determine if you are eligible to purchase PT Programs. HLA DRUG HYPERSENSITIVITY - PGX2 Analytes/procedures in bold type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services (CMS). Analyte/Procedure Challenges per Shipment Number of Shipments HLA‑B*15:02 3 Two shipments per year HLA‑B*57:01 3 Additional Information Designed for laboratories that provide HLA‑B*57:01 testing to identify risk of hypersensitivity to abacavir and HLA-B*15:02 testing to identify risk of hypersensitivity to carbamazepine. The intended response is qualitative (presence/absence of the allele). This Survey is not appropriate for laboratories that perform molecular HLA typing. For HLA typing proficiency testing, please consult the HLA Molecular Typing (DML) Survey. Program Information Three 25.0‑μg extracted DNA specimens Includes allele detection (genotyping) and/or interpretive challenges Shipping Schedule Shipment A: April 20 Shipment B: September 14 Guest Log in/Register Customers Who Bought This Item Also Bought HLA DISEASE ASSOCIATION-DRUG RISK VIEW DETAILS > CLASS I & II HLA MOLECULAR TYPING VIEW DETAILS >